Header Logo

Connection

RADEK SKODA to Myeloproliferative Disorders

Back to Details
This is a "connection" page, showing publications RADEK SKODA has written about Myeloproliferative Disorders.
RADEK SKODA
Connection Strength
18.155
Myeloproliferative Disorders
  1. Loss of Socs2 improves molecular responses to IFNa in a mouse model of myeloproliferative neoplasms driven by JAK2-V617F. Leukemia. 2025 Apr; 39(4):876-887.
    View in: PubMed
    Score: 0.867
  2. Loss of Dnmt3a increases self-renewal and resistance to pegIFN-a in JAK2-V617F-positive myeloproliferative neoplasms. Blood. 2024 06 13; 143(24):2490-2503.
    View in: PubMed
    Score: 0.824
  3. The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN. Blood Adv. 2024 05 14; 8(9):2312-2325.
    View in: PubMed
    Score: 0.819
  4. IL-1? promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells. Blood Adv. 2024 03 12; 8(5):1234-1249.
    View in: PubMed
    Score: 0.809
  5. Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms. Blood. 2023 04 27; 141(17):2127-2140.
    View in: PubMed
    Score: 0.762
  6. Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood. 2023 04 20; 141(16):1909-1921.
    View in: PubMed
    Score: 0.761
  7. Inhibition of interleukin-1? reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm. Nat Commun. 2022 09 13; 13(1):5346.
    View in: PubMed
    Score: 0.730
  8. JAK2-V617F and interferon-a induce megakaryocyte-biased stem cells characterized by decreased long-term functionality. Blood. 2021 04 22; 137(16):2139-2151.
    View in: PubMed
    Score: 0.663
  9. Myeloproliferative Neoplasms: The Long Wait for JAK2-Mutant Clone Expansion. Cell Stem Cell. 2021 03 04; 28(3):359-361.
    View in: PubMed
    Score: 0.656
  10. Mouse models of myeloproliferative neoplasms for pre-clinical testing of novel therapeutic agents. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2021 Mar; 165(1):26-33.
    View in: PubMed
    Score: 0.653
  11. MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineages. Blood. 2020 11 26; 136(22):2591-2595.
    View in: PubMed
    Score: 0.644
  12. JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms. Blood. 2019 11 21; 134(21):1832-1846.
    View in: PubMed
    Score: 0.600
  13. [Myeloproliferative neoplasms - Update on diagnosis and treatment]. Ther Umsch. 2019; 76(9):487-495.
    View in: PubMed
    Score: 0.565
  14. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis. J Exp Med. 2016 07 25; 213(8):1479-96.
    View in: PubMed
    Score: 0.476
  15. Pathogenesis of myeloproliferative neoplasms. Exp Hematol. 2015 Aug; 43(8):599-608.
    View in: PubMed
    Score: 0.445
  16. Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN. Blood. 2015 Mar 26; 125(13):2131-40.
    View in: PubMed
    Score: 0.429
  17. Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F. J Exp Med. 2014 Oct 20; 211(11):2213-30.
    View in: PubMed
    Score: 0.421
  18. Somatic mutations in calreticulin can be found in pedigrees with familial predisposition to myeloproliferative neoplasms. Blood. 2014 Apr 24; 123(17):2744-5.
    View in: PubMed
    Score: 0.408
  19. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014 Apr 03; 123(14):2220-8.
    View in: PubMed
    Score: 0.401
  20. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood. 2010 Mar 11; 115(10):2003-7.
    View in: PubMed
    Score: 0.303
  21. Hereditary myeloproliferative disorders. Haematologica. 2010 Jan; 95(1):6-8.
    View in: PubMed
    Score: 0.303
  22. Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. Blood. 2009 Feb 26; 113(9):2022-7.
    View in: PubMed
    Score: 0.281
  23. The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders. Haematologica. 2008 Dec; 93(12):1890-3.
    View in: PubMed
    Score: 0.276
  24. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008 Apr 15; 111(8):3931-40.
    View in: PubMed
    Score: 0.263
  25. Myeloproliferative disorders: a time of new definitions. Outflow from New Horizons in Haematology Meeting, 9-10 March 2007. Eur J Haematol Suppl. 2007 Oct; (68):1.
    View in: PubMed
    Score: 0.259
  26. Advances in the understanding and management of myeloproliferative disorders. Eur J Haematol Suppl. 2007 Oct; (68):2-4.
    View in: PubMed
    Score: 0.259
  27. Update on the impact of the JAK2 mutation on signalling pathways in myeloproliferative disorders. Eur J Haematol Suppl. 2007 Oct; (68):5-8.
    View in: PubMed
    Score: 0.259
  28. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood. 2007 Jul 01; 110(1):375-9.
    View in: PubMed
    Score: 0.249
  29. The genetic basis of myeloproliferative disorders. Hematology Am Soc Hematol Educ Program. 2007; 1-10.
    View in: PubMed
    Score: 0.246
  30. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006 Aug 15; 108(4):1377-80.
    View in: PubMed
    Score: 0.235
  31. Chronic myeloproliferative disorders--introduction. Semin Hematol. 2005 Oct; 42(4):181-3.
    View in: PubMed
    Score: 0.225
  32. Gain of function, loss of control - a molecular basis for chronic myeloproliferative disorders. Haematologica. 2005 Jul; 90(7):871-4.
    View in: PubMed
    Score: 0.221
  33. Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders. Blood Rev. 2005 Jan; 19(1):1-13.
    View in: PubMed
    Score: 0.214
  34. Chronic myeloproliferative disorders: molecular markers and pathogenesis. Hematol J. 2004; 5 Suppl 3:S122-5.
    View in: PubMed
    Score: 0.200
  35. Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosis. Nat Commun. 2023 10 12; 14(1):6414.
    View in: PubMed
    Score: 0.197
  36. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood. 2003 Sep 01; 102(5):1869-71.
    View in: PubMed
    Score: 0.191
  37. Genomic profiling for clinical decision making in?myeloid neoplasms and acute leukemia. Blood. 2022 11 24; 140(21):2228-2247.
    View in: PubMed
    Score: 0.185
  38. Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs. Blood Adv. 2022 09 13; 6(17):5171-5183.
    View in: PubMed
    Score: 0.182
  39. Myeloproliferative disorders: complications, survival and causes of death. Ann Hematol. 2000 Jun; 79(6):312-8.
    View in: PubMed
    Score: 0.156
  40. Loss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation. Cancer Discov. 2019 09; 9(9):1228-1247.
    View in: PubMed
    Score: 0.146
  41. Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. J Clin Invest. 2019 03 04; 129(4):1596-1611.
    View in: PubMed
    Score: 0.143
  42. The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14. Haematologica. 2019 04; 104(4):710-716.
    View in: PubMed
    Score: 0.140
  43. Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms. Blood. 2017 12 28; 130(26):2848-2859.
    View in: PubMed
    Score: 0.130
  44. Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations. Ann Hematol. 2017 Mar; 96(3):393-404.
    View in: PubMed
    Score: 0.122
  45. Angiogenic factors are increased in circulating granulocytes and CD34+ cells of myeloproliferative neoplasms. Mol Carcinog. 2017 02; 56(2):567-579.
    View in: PubMed
    Score: 0.119
  46. Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature. 2014 Aug 07; 512(7512):78-81.
    View in: PubMed
    Score: 0.103
  47. Dkk3 levels in patients with myeloproliferative neoplasms. Thromb Res. 2014 Feb; 133(2):218-21.
    View in: PubMed
    Score: 0.099
  48. JAK2 V617F-mutated myeloproliferative neoplasia developing five years after wild-type JAK2 acute myeloid leukemia: a case report. Acta Haematol. 2013; 129(1):23-5.
    View in: PubMed
    Score: 0.091
  49. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol. 2009 Nov; 6(11):627-37.
    View in: PubMed
    Score: 0.074
  50. Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues. Leukemia. 2009 Oct; 23(10):1708-15.
    View in: PubMed
    Score: 0.073
  51. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status. Br J Haematol. 2009 Jul; 146(2):150-7.
    View in: PubMed
    Score: 0.072
  52. BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features. Leukemia. 2008 Nov; 22(11):1975-89.
    View in: PubMed
    Score: 0.070
  53. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood. 2008 Feb 01; 111(3):1686-9.
    View in: PubMed
    Score: 0.065
  54. ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation. Proc Natl Acad Sci U S A. 2015 Apr 14; 112(15):4642-7.
    View in: PubMed
    Score: 0.027
  55. Stalled cerebral capillary blood flow in mouse models of essential thrombocythemia and polycythemia vera revealed by in vivo two-photon imaging. J Thromb Haemost. 2014 Dec; 12(12):2120-30.
    View in: PubMed
    Score: 0.026
  56. Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica. 2009 Jan; 94(1):38-45.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.